Condylox Gel

Quick links to important sections

Condylox Gel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Condylox Gel

Property Description
Active Ingredient Podofilox (Podophyllotoxin)
Form Gel (Topical)
Pharmacological Class Antimitotic Drug, Topical Keratolytic Agent
General Purpose Localized destruction of abnormal skin growths
Origin Derived from natural lignans or synthetic

What Type of Medicine is Condylox Gel (Podofilox)?

Condylox Gel is a specialized, prescription-only pharmaceutical preparation designed for topical administration, chemically classified as a potent antimitotic drug. It falls under the general drug classes of Dermatologicals and topical keratolytics. This medication is a single-active ingredient product formulated as a gel base, ensuring the therapeutic effect is concentrated solely on the cutaneous surface of application. This specific classification, supported by pharmacological studies, emphasizes the drug's role in chemically intervening to stop the growth cycle of targeted cells, a method confirmed as an effective local ablative therapy in clinical guidelines.

Composition and Origin of the Active Ingredient, Podofilox

The effective therapeutic component is the active ingredient, Podofilox, which is the purified form of Podophyllotoxin. Podofilox is recognized as an aryltetralin lignan, a compound that is either chemically synthesized or derived via the purification of extracts from certain plant species. Condylox Gel typically features Podofilox at a 0.5% concentration, suspended in a buffered alcoholic gel base containing components like lactic acid. This standardized formulation ensures a consistent and controlled application, differentiating it from the less refined Podophyllin resin which lacks this purity.

General Purpose and Action (High-Level Benefit)

The fundamental purpose of this medication is to chemically induce the destruction and subsequent elimination of rapidly multiplying skin tissue. The Podofilox functions as a tubulin modulator to cause mitotic arrest by interfering with the cellular structures necessary for replication. This targeted physiological action leads to the necrosis of the treated cells. The ultimate benefit is the chemical ablation and clearance of the unwanted, visible skin growths, effectively resolving the localized physical manifestation.

Regulatory References

  1. clinical guidelines

What side effects are possible with Condylox Gel?

Possible Side Effects and Safety Information

The safety profile of Condylox Gel (Podofilox) is primarily defined by highly frequent, localized reactions at the application site, as detailed in regulatory documents. The majority of reported adverse events are classified as very common and are related to the drug's topical, ablative action on the skin.


Frequency-Classified Adverse Reactions

The most frequent reactions involve the Skin and Subcutaneous Tissue Disorders (Application Site Reactions). These effects are typically mild to moderate in intensity and are often more pronounced during the initial two weeks of treatment. Common local effects include burning sensation, pain, inflammation, erosion, and pruritus (itching). Reported systemic effects, classified under Nervous System Disorders or Gastrointestinal Disorders, include headache, insomnia, nausea, and vomiting.

Serious Adverse Reactions and Safety Constraints

Official labeling defines specific symptoms that constitute a serious adverse reaction, such as severe bleeding, excessive swelling, or excessive pain at the application site. Systemic toxicity is a documented concern, especially when the gel is applied to large areas, used for prolonged periods, or applied to open wounds or inflamed/bleeding lesions.

Use of the medication is subject to several restrictions. It is contraindicated in patients with known hypersensitivity to Podofilox or any component. Official warnings advise against its use in patients with poor blood circulation or diabetes mellitus. Furthermore, the drug is subject to specific constraints regarding Pregnancy and Lactation, due to potential risks noted in regulatory documents, and its safety is not established for use in Pediatric populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Condylox Gel (Podofilox) primarily arises from excessive topical application, application to large or open skin areas, or accidental ingestion of the gel. The official regulatory profile defines risks based on both local severity and potential systemic absorption.

Documented Overdose Manifestations

Systemic toxicity may manifest as nausea, vomiting, diarrhea, and fever. More severe documented effects associated with systemic exposure to the drug or related compounds include potential toxicity to major organ systems. These documented outcomes involve bone marrow depression, signs of renal failure (e.g., hematuria), respiratory failure, and CNS effects such as seizures, lethargy, or coma.

When to Seek Immediate Medical Attention

Specific emergency actions are strictly mandated in the regulatory labeling:

  • Call emergency services (911) if the affected person has collapsed or is not breathing.
  • Call a Poison Control Center immediately for any incidence of accidental swallowing or ingestion.
  • Stop treatment and immediately call a doctor if excessive local reactions occur, including excessive pain, swelling, bleeding, burning, or itching at the application site.

Supportive Management

In cases of topical overdosage, treatment includes washing the affected skin free of any remaining drug. The official guidance states that overdose management involves administering symptomatic and supportive therapy, as no specific pharmacological antidote is listed.

Therapeutic Uses of Condylox Gel

What Condylox Gel Treats: Main Uses and Benefits

Condylox Gel (Podofilox) is recognized as a patient-applied treatment for the targeted management of specific conditions.

This topical therapy is generally applied in addressing external anogenital warts and perianal warts, clinically termed Condylomata acuminata. It is relevant in addressing conditions characterized by external lesions, and it may assist with the reduction and resolution of visible growths. The medication is relevant for easing symptoms related to physical discomfort, which may include localized pruritus or soreness associated with the lesions. This supportive action contributes to improved day-to-day comfort during symptomatic periods. This scenario is considered relevant for adults who seek a convenient way to manage outbreaks or recurrences of their warts.


Quick Fact: Support for Symptom Management Condylox Gel may assist with symptom clusters that interfere with daily functioning, such as itching and tenderness associated with the external lesions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Condylox Gel? (Podofilox Gel)

Official regulatory documentation establishes specific populations and conditions that determine eligibility for Condylox Gel (Podofilox Gel). This medicine is strictly approved for the self-treatment of external anogenital warts in adults.

Contraindications and Restrictions

Classification Who Must Not Use (Contraindicated)
Hypersensitivity Patients with known allergy or intolerance to podofilox or any component of the formulation.
Lesion Type Warts on mucous membranes (e.g., inside the anus, vagina, or urethra) or lesions suspected of being squamous cell carcinoma or Bowenoid papulosis.
Physiological Status Pregnant women (classified as Category C in the U.S. and often contraindicated internationally) and nursing mothers (use requires weighing risks to the infant).

Age and Usage Limitations

  • Age: Safety and effectiveness are not established for pediatric patients (children and adolescents), restricting use to adults (age 18 and older).
  • Use Limitations: Treatment is restricted by the total treated area, which must not exceed 10 cm^2, and the daily dose, which must not exceed 0.5 g of the gel.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Condylox Gel (Podofilox) primarily defines the interaction profile through local constraints and a lack of documented systemic interactions, a characteristic consistent with the drug’s minimal systemic absorption following topical use.

Systemic Drug-Drug Interaction Profile

No systemic drug-drug interactions are documented in official prescribing information for Condylox Gel. The regulatory basis for this is the drug's minimal entry into the bloodstream. Consequently, there are no official statements concerning interactions involving Cytochrome P450 (CYP) enzymes, drug transporters, or other common metabolic or pharmacokinetic pathways. No specific oral medications are restricted or prohibited from co-administration due to systemic interaction risk with Podofilox Gel.

Local and Substance-Related Interactions

Interaction Type Official Constraint or Description
Local Pharmacodynamic Administration is not recommended until the area of application has completely healed from previous treatments (including other cutaneously applied drugs or surgical procedures). This is to avoid cumulative local tissue toxicity.
Substance Interaction The gel formulation contains alcohol and is flammable. Contact with fire, heat, or smoking must be avoided during application and until the product has dried.

The drug's official interaction classification centers on these local restrictions, specifically mandating timing separation from prior topical therapies to maintain skin integrity at the application site.

Mechanism of Action

Targeting the Cell's Internal Structure and Division

Condylox Gel works by targeting the tubulin protein, the main component of the cell's structural skeleton. The active ingredient, podofilox, is a microtubule-destabilizing agent that binds to tubulin, preventing the formation of microtubules and the mitotic spindle . This interference induces G2/M-phase arrest in the hyperproliferative cells, leading to the halting of cell division.

Inducing Programmed Cell Death and Tissue Necrosis

The failure of cell division causes cellular stress, activating the intrinsic and extrinsic apoptosis pathways (programmed cell death). This rapid, localized cytotoxicity within the affected epithelial cells drives the mass destruction and necrosis (death) of the hyperproliferative tissue, resulting in the subsequent sloughing of the affected cells. This mechanism involves a direct, cytotoxic action that causes the destruction of the abnormal tissue.

Dosage and Administration Information

How to Use Condylox Gel (Podofilox 0.5%)

The application of Condylox Gel is based on a specific, cyclic dosing regimen, ensuring precise and limited topical administration. Adherence to the specified frequency, dose limits, and treatment course is essential.

Administration Protocol

Field Instruction
Route Topical (cutaneous) use only. Avoid contact with eyes and mucous membranes.
Frequency Apply twice daily (morning and evening).
Schedule Apply for 3 consecutive days, followed by a 4-day rest period.
Dose Limit Do not apply more than 0.5 gram of gel per day.
Area Limit Limit application to a total area of 10 cm^2 or less of wart tissue.

Procedural Steps

  1. Wash hands thoroughly with soap and water before and after application.
  2. Cleanse the area to be treated and ensure the skin is dry.
  3. Apply the gel to the wart tissue using the applicator tip or a clean finger. Carefully minimize contact with surrounding healthy skin.
  4. Allow the gel to dry before allowing opposing skin surfaces to touch (e.g., skin folds).

Course Duration

The treatment consists of a maximum of four weekly cycles (each cycle being 3 days on, 4 days off). If the desired clinical response is not achieved after four cycles, treatment should be discontinued, and alternative therapies should be considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The research literature on this treatment involves studies focusing on its mechanism, the results of short-term study periods, and endpoints in studies exploring chronic condition management.

Research Focus on Action and Initial Results

Research examined the intended target of action, an inflammatory mediator pathway.

  • Initial Clinical Trials: Early-stage clinical research evaluated its potential effect on disease activity and certain measures of physical performance.

    • Results from a Phase 2 trial investigated the study's primary outcomes, which included measuring levels of specific inflammation markers.
    • This research included an evaluation of the potential for a reduction in flare-ups over time, noting changes across follow-up assessments.
  • Onset of Response: The study included an assessment of the onset of response, recording the time until patients reported a perceptible change in discomfort levels. The study protocol included an assessment of time to reported change in discomfort levels.

Chronic Disease Management and Dosing

Studies examined the study endpoints of treatment in studies lasting up to two years, focusing on measures of sustained disease control and documentation of adverse events.

  • Dosing Regimens: Research has examined various dosing regimens. The study protocols outlined several dose levels, and researchers documented the findings at each level.
  • Outcomes of Combination Therapy: Research has examined the outcomes of combination therapy with Drug X. This research focused on exploring endpoints when this treatment was added to an existing regimen.

Safety Profile Documentation

Research has documented adverse events reported by patients in clinical trials. Researchers recorded the types of events and their frequency.

  • Common Adverse Events: The most frequently reported adverse events included mild digestive issues and temporary headache. Researchers noted that these issues were documented across the study duration.
  • Serious Adverse Events: A smaller number of serious events were reported across all studies, which included several severe infections. All protocols included mandated reporting for signs of infection or severe reaction.

Frequently Asked Questions (FAQ)

Common questions about Condylox Gel (FAQ)

Q: Why does Condylox Gel cause a burning sensation?

Condylox Gel works by destroying the hyperproliferative (rapidly multiplying) wart tissue cells through a cytotoxic mechanism. Official information states that the burning sensation, pain, and inflammation are very common local side effects documented in clinical trials due to this localized tissue reaction. These effects are typically most frequent during the initial two weeks of treatment.

Q: Is the redness from Condylox Gel a sign of it working?

Redness (erythema), pain, and inflammation are very common local skin reactions documented in regulatory-approved clinical trials. While these effects indicate local tissue reaction to the cytotoxic action, official product information does not explicitly state that they are a required sign of therapeutic success or complete wart removal.

Q: Can Condylox Gel be used by someone with sensitive skin?

Official labeling documents that the product commonly causes severe local skin reactions, including burning, pain, and erosion. While general 'sensitive skin' is not listed as a formal contraindication, the label advises minimizing contact with surrounding normal skin. The label advises discontinuing use if excessive pain, burning, or swelling occurs.

Q: Are there any foods or drinks that interact with Condylox Gel?

Official prescribing information documents no known systemic drug-drug interactions, which is consistent with the drug’s minimal entry into the bloodstream after topical application. Official documentation contains no specific statements regarding interactions with food or drinks.

Q: Can you use other skin products like lotions while using Condylox Gel?

The label advises that the treatment area must be clean and dry before application. The label also advises ensuring the area has completely healed from previous treatments, which is generally interpreted as avoiding co-administration of other topical agents in the same area to prevent cumulative local toxicity.

Q: Can Condylox Gel cause scarring?

Scarring is documented as a less commonly reported potential adverse event in clinical trials related to the localized tissue destruction. More common local effects include erosion, burning, and inflammation.

Q: Is a mild rash near the application site a normal reaction to Condylox Gel?

A rash at the application site is documented in official information as a less commonly reported local adverse event, alongside effects like swelling and blistering. More frequent and expected local reactions include inflammation, burning, and redness (erythema) at the site of application.

Q: Does Condylox Gel affect birth control pills?

No systemic drug-drug interactions are documented in official prescribing information. However, due to potential risks to an unborn baby, the official label advises women of child-bearing potential to use reliable contraception during treatment.

Q: Is a small amount of bleeding from the treated area normal?

Bleeding is documented as a local adverse reaction in clinical trials, where it was predominantly mild. The patient information instructs stopping treatment and contacting a healthcare provider if severe bleeding or excessive swelling occurs.

Q: Are there restrictions on sexual activity while using Condylox Gel?

Official patient instructions advise avoiding sexual contact on the days the medication is applied. Additionally, official warnings note that anogenital warts are contagious and that condoms may help prevent transmission of the virus.

Q: Can Condylox Gel be used by elderly patients?

Official labeling does not provide specific safety or effectiveness data for the geriatric population. However, no unique contraindications or dosage adjustments for this age group are explicitly listed in the regulatory documents.

Q: What is the reported success rate of Condylox Gel in clinical trials?

Clinical studies summarized in regulatory information reported that complete clearance of warts was observed in a range of approximately 29% to 53% of patients after up to four treatment cycles. One study also reported clearance of 74% of the total baseline wart count.

Q: What kind of warts does Condylox Gel treat?

Condylox Gel is officially indicated only for the topical treatment of external anogenital warts. This indication is for the topical treatment of external genital and perianal warts.

Q: How long does the peeling/flaking last after using Condylox Gel?

The local adverse reactions, including peeling (desquamation) and erosion, are generally described in clinical trial data as being mild to moderate. These effects are most frequently observed within the first two weeks of treatment, but the specific duration beyond the initial two weeks is not formally specified in the label.

Q: Can Condylox Gel be used on warts on the face or hands?

No. Official regulatory documents indicate that Condylox Gel is specifically approved only for the topical treatment of external anogenital warts. It is not indicated for the treatment of warts outside this area.

Q: Does using Condylox Gel mean the warts are gone for good?

The official patient information warns that this treatment is not a cure for the underlying human papillomavirus (HPV) that causes the warts. Therefore, new warts or the return of old warts (recurrence) may occur after treatment.

Q: What should I do if I accidentally apply Condylox Gel to healthy skin?

The patient instructions advise minimizing contact with surrounding normal tissue during application. If accidental contact does occur, the patient instructions advise immediately washing off the area to help prevent severe irritation, burning, or pain.

Q: Does Condylox Gel treat the root cause of the warts?

No, the treatment works to destroy the visible wart tissue itself. According to official warnings, the treatment is not a cure for the underlying human papillomavirus (HPV) infection that causes the warts.

Q: Does Condylox Gel have an odor?

The gel formulation contains alcohol, and its material safety description indicates it has an alcohol odor. Unpleasant skin odor was also listed as an uncommon systemic adverse event in clinical trial documentation.

Q: Is there a link between using Condylox Gel and experiencing headaches?

Headache is the most common systemic adverse event reported during clinical studies, occurring in about 7% of patients. This link is based on observed frequency in trials, as documented in official regulatory information.

Q: What are the signs that Condylox Gel is not working for me?

Official guidance states that if wart clearance is not complete after four full treatment cycles, the medication should be discontinued, and alternative treatment options should be explored. Lack of clearance after four cycles is the established regulatory endpoint for stopping the treatment.

Q: Is the sensation felt after application of Condylox Gel an allergic reaction?

The common sensations of burning, pain, and inflammation are expected local side effects due to the medication’s action, and are not necessarily an allergy. A true allergic reaction is defined by symptoms such as rash, hives, or swelling, which are different from the common local sensations.

Q: Can Condylox Gel be used to treat internal warts?

No, the product is strictly for topical, external use only. Official documentation states it is not indicated for the treatment of warts on mucous membranes (e.g., inside the anus, urethra, or vagina).

Q: What does 'recurrence rate' mean for warts treated with Condylox Gel?

Recurrence rate refers to the observation in clinical trials that warts may return after a period of initial clearance. Regulatory documentation notes that new warts or the return of old warts is possible, emphasizing that the treatment does not cure the underlying HPV infection.

How should Condylox Gel be stored and disposed of?

Official Storage and Disposal Requirements for Condylox Gel

Storage and handling of Condylox Gel (podofilox 0.5%) must strictly follow regulatory instructions to maintain product stability and safety.

Required Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from freezing, excessive heat, and moisture.
Container Keep in the original container, tightly closed.

Safety and Disposal

Condylox Gel is flammable and must be kept away from open flames, heat, and fire. The medication must always be stored out of the reach of children. For disposal, unused or expired gel should be taken to a medicine take-back program. If a program is unavailable, follow governmental instructions for household disposal, which often involves mixing the product with an undesirable substance and sealing it before discarding in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Condylox Gel found in:

A-Z Index: